BeyondSpring (BYSI) Other financing activities (2020 - 2026)
BeyondSpring's (BYSI) quarterly Other financing activities came in at $280000.0 in Q1 2026, down 89.71% quarter-over-quarter from $2.7 million in Q3 2025.
Powered by 
Analysis
BeyondSpring (BYSI) Other financing activities (2020 - 2026) Analysis & Trends
BeyondSpring has disclosed Other financing activities across 4 years of filings, most recently posting $280000.0 for Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $280000.0; the TTM figure through Jun 2026 stood at $3.0 million (up 50.0% YoY), while the FY2025 annual figure was $2.7 million, down 86.4% from the prior year.
- Other financing activities came in at $280000.0 for Q1 2026 at BeyondSpring, down from $2.7 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $2.7 million in Q3 2025 to a low of $280000.0 in Q1 2026.
- Average Other financing activities over 3 years is $1.7 million, with a median of $2.0 million recorded in 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 280,000.00 |
| Sep 30, 2025 | 2.72 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Dec 31, 2020 | 278,000.00 |